Ampio Pharmaceuticals Inc
OTC:AMPE
Ampio Pharmaceuticals Inc
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Englewood, Colorado and currently employs 8 full-time employees. The company went IPO on 2011-05-19. The firm is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The firm is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Englewood, Colorado and currently employs 8 full-time employees. The company went IPO on 2011-05-19. The firm is focused on the preclinical development of AR-300, and is conducting studies to evaluate the efficacy of AR-300 in osteoarthritis-related pain. The firm is primarily targeting the clinical development of AR-300 for the treatment of osteoarthritis of the knee (OAK). AR-300 is a small-molecule formulation that has demonstrated anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
